# Data Sheet (Cat.No.T13467)

TargetMol

## (±)-Enitociclib

### Chemical Properties



CAS No. : 1610358-53-6

Formula: C19H18F2N4O2S

Molecular Weight: 404.43

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | (±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152, a highly selective inhibitor of PTEF/CDK9. |
| Targets(IC50) | Apoptosis,CDK,DNA/RNA Synthesis |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 50 mg/mL (123.63 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (6.18 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL |
| 5 mM | 0.4945 mL | 2.4726 mL | 4.9452 mL |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4726 mL |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Luecking, et al. Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017; 77(13 Suppl):Abstract nr 984. doi:10.1158/1538-7445.AM2017-984

Zhang G M, Huang S S, Ye L X, et al. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacological Research. 2022: 106464.



Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481